Metformin as an Adjunct to Chemoradiotherapy in Locally Advanced Cervical Cancer: Insights on Safety, Tolerability, and Feasibility from a Phase II Randomized Trial

Highlight

• Metformin combined with chemoradiotherapy is safe and well-tolerated in locally advanced cervical cancer patients.
• The addition of metformin does not increase severe adverse events compared to chemoradiotherapy alone.
• MRI and tumor biopsy assessments for hypoxia biomarkers were successfully implemented throughout the study, affirming feasibility.
• Initial safety evaluations show no concerning early increase in tumor hypoxia with metformin administration.

Study Background and Disease Burden